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ABSTRACT
The elucidation of better treatments for solid tumors and especially malignant
glial tumors is a priority. Better understanding of the molecular underpinnings of
treatment response and resistance are critical determinants in the success for this
endeavor. Recently, a battery of novel tools have surfaced that allow to interrogate
tumor cell metabolism to more precise extent than this was possible in the earlier
days. At the forefront of these developments are the extracellular flux and carbon
tracing analyses. Through utilization of these techniques our group made the recent
observation that acute and chronic c-MET inhibition drives fatty acid oxidation that
in turn can be therapeutically targeted for drug combination therapies. Herein, we
summarize and comment on some of our key findings related to this study.

INTRODUCTION

instance, oxidative energy metabolism is suppressed by
HIF1α, a transcription factor whose stability and turn over
depends on oxygen levels.
Blocking the Warburg effect might lead to inhibition
of tumor growth given its implication in biosynthesis
of macromolecules [2]. However, tumor cells possess
metabolic plasticity that might allow them to reactivate
oxidative energy metabolism to survive following
inhibition of a certain molecular target. This phenomenon
has been observed following drug treatments in various
model systems. In the setting of malignant melanoma, it
has been shown that BRAF-inhibitor resistant melanoma
harboring the BRAF V600E mutation activate oxidative
phosphorylation as a means to escape from therapy [3, 4].
In turn, such model system become sensitive to inhibitors
of the electron transport chain, such as metformin,
phenformin or 2,4 dinitrophenol. Molecular analysis has
shown that metabolic reprogramming in the melanoma
model system described above was in part mediated by
the transcription factor PGC1α [5], a driver of oxidative
metabolism in normal and tumor cells. In the melanoma
model systems, MITF was a strong regulator of PGC1α
and thus mitochondrial abundance and oxidative energy

In the 1920s of the last century biochemist Otto
Warburg made the remarkable and astonishing discovery
that malignant cells heavily utilize glucose and metabolize
it to lactic acid despite the presence of sufficient oxygen
[1]. This paradoxical and energetic inefficient process was
then coined as “aerobic glycolysis”. The implications of
his findings were considered as far-reaching and were
lauded with the Nobel prize in medicine and physiology a
couple of years later.
While at the first glance it may appear to be intuitive
that cancer cells should facilitate energy production
through most efficient means, aerobic glycolysis enables
tumor cells to retain carbons and pass them on to
biosynthesis of macromolecules, e.g. purines/pyrimidines
(nucleotide and associated DNA synthesis), amino acids,
fatty acids and cholesterol, that are essential for tumor
cell survival and proliferation. Glycolysis in tumor cells
is tightly regulated by a couple of known transcription
factors: c-Myc, N-Myc, HIF1α and others through binding
to the promoter regions of key glycolytic enzymes and
transporters and are facilitators of the Warburg effect. For
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metabolism. Silencing of PGC1α suppressed the oxidative
phenotype and enhanced cell killing of melanoma cells
following BRAF-inhibitor treatment in vitro and in vivo.
Conversely, over-expression of PGC1α suppressed the
reduction in cellular viability elicited by BRAF-inhibitors
in BRAF V600E mutated melanoma model systems.
Similar to the observations in melanoma, our group
made the recent and related discovery that in glioblastoma
targeting MET signaling, a receptor kinase that connects to
the ERK signaling pathway, elicits an increase of oxidative
metabolism through activation of fatty acid oxidation
(FAO) [6]. MET signaling remains a critical pathway
in glioblastomas, but thus far akin to other molecular
targets therapeutics targeting of MET fell rather short of
expectations [7, 8]. The causes are multiple and include the
fact that inhibitors may not cross the blood brain barrier
very well. However, other factors may involve primary or
secondary drug resistance. Guided by a transcriptome and
comprehensive metabolite analysis we recently made a
couple of intriguing observations that following treatment
with the MET inhibitor, crizotinib, glioblastoma cells
showed evidence of metabolic reprogramming, rendering
them sensitive to combination treatments, involving

inhibitors of FAO (etomoxir) and OXPHOS (metformin
and oligomycin) along with crizotinib (Figure 1). We took
a complementary approach to highlight the dependency
on FAO further following c-MET inhibition by utilizing
both extracellular flux (on the Seahorse analyzer) and
carbon tracing analyses. Both the fatty acid oxidation
assay and U-13C-palmitic acid tracing analysis confirmed
the increased utilization and dependence on long-chain
fatty acids since palmitic acid derived carbons enriched
the TCA-cycle metabolites, indicative of enhanced
beta-oxidation. Most notably, we found that the m+2
isotopologue of citric acid was enriched by palmitic acid
derived carbons [6]. We noted an increase of glucose
derived carbons in citric acid, while the m+2 citric acid
isotopologue was decreased, suggesting reduced glucose
oxidation, but increased anaplerosis, which may support
operation of the TCA-cycle to further nourish the reaction
of fatty acid derived acetyl-CoA with citric acid. To
our surprise, glutamine contributed less to anaplerosis
following c-MET inhibition, which was indicated by
decreased labeling of citric acid by glutamine.
Our transcriptome analysis suggested up-regulation
of PGC1α along with transcriptional activation of PPARA

Figure 1: Chronic MET inhibition facilitates metabolic reprogramming to drive fatty acid oxidation. The receptor kinase
c-MET can be inhibited by crizotinib. Chronic c-MET inhibition results in paradoxical reactivation of ERK followed by CREB and PGC1α
upregulation. In addition, there is an enhancement of fatty acid oxidation (FAO) coupled with up-regulation of genes involved in FAO
(ACADVL, ACADSB, CPT2, FABP3). Likely, increased anaplerosis contributes to proper running of the tricarboxylic acid cycle. Related
to this phenotype, there is activation of OXPHOS (oxidative phosphorylation) and enhanced mitochondrial abundance.
www.impactjournals.com/oncoscience
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